Patent claims

5 1. Compounds of formula (I):

$$R3$$
 X
 O
 $R4$
 $R5$
 $R1$
 $R6$
 $R6$
 $R4$
 $R5$

wherein

10

R1 is a hydrogen atom, a heteroalkyl, heteroaralkyl, heterocycloalkyl, hydroxy or alkyloxy group, R2 is a hydrogen atom or a hydroxy group, or R1 and R2 together are part of a 5- or 6-membered ring;

15

R3 is a hydrogen atom, a hydroxy, alkyloxy, amino, alkylamino or dialkylamino group or a halogen atom;

20

R4 and R5 are, each independently of the other, a hydrogen atom, a halogen atom, a hydroxy, amino, nitro or thiol group, an alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl or heteroaralkyl radical or a glycosyloxy group;

25

heteroalkyl, heteroaralkyl, R6 is an alkyl, heteroaryl, aralkyl, cycloalkyl, heterocycloalkyl or formula being group of R6 not а aryl group, -CHR8-CO-NR9R9', wherein R8, R9 and R9' are, each independently of the others, a hydrogen atom, an

alkyl, heteroalkyl, heteroaralkyl, heteroaryl, aralkyl, cycloalkyl, heterocycloalkyl or aryl group, or R9 and R9' together are part of a heterocycloalkyl or heteroaryl ring system, and

5

X is a group of formula NR7, O, S, SO, SO₂, SO₂NH, PO_2NH , CH_2 , CHMe or CO, R7 being a hydrogen atom, an alkyl or aralkyl group;

- or a pharmacologically acceptable salt, solvate, hydrate or pharmacologically acceptable formulation thereof.
- Compounds according to claim 1, wherein R1 is a
 hydrogen atom.
 - Compounds according to claim 1 or 2, wherein R2 is a hydrogen atom.
- 20 4. Compounds according to one of claims 1 to 3, wherein R3 is a hydrogen atom or a hydroxy group.
- 5. Compounds according to one of claims 1 to 4, wherein R4 is a hydrogen atom, an -OH, -OCH₂COOH, -COOH, -OCH₂COOCH₃, C_1 - C_4 alkyloxy or glycosyloxy group or a halogen atom.
 - 6. Compounds according to one of claims 1 to 4, wherein R4 is a β -D-glucosyloxy group.
- 30
- 7. Compounds according to one of claims 1 to 6, wherein R5 is a hydrogen atom, an -OH, -OCH₂COOH, -COOH, -OCH₂COOCH₃, C_1 - C_4 alkyloxy or glycosyloxy group or a halogen atom.

35

- 8. Compounds according to one of claims 1 to 6, wherein R5 is a hydrogen atom.
- 5 9. Compounds according to one of claims 1 to 8, wherein X is an NH group.
- 10. Pharmaceutical compositions comprising a compound according to claims 1 to 9 as active ingredient and, optionally, carrier substances and/or adjuvants.
 - 11. Use of a compound or of a pharmaceutical composition according to one of claims 1 to 10 in inhibiting factor Xa.
- 12. Use of a compound or of a pharmaceutical composition according to one of claims 1 to 10 in the treatment and/or prevention of thromboembolic conditions, arterial restenosis, septicaemia, cancer, acute inflammation or other conditions mediated by factor Xa activity.

15

13. Use of a compound or of a pharmaceutical composition according to one of claims 1 to 10 for utilisation in vascular surgery.